68281-43-6

Basic information

• Product Name: 6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE-2-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: ETHYL 6-CHLORO-3,4-DIHYDRO-2H-1,4-BENZOXAZINE-2-CARBOXYLATE;6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE-2-CARBOXYLIC ACID ETHYL ESTER;Ethyl 6-chloro-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxylate
• CAS NO: 68281-43-6
• Molecular Formula: C₁₁H₁₂ClNO₃
• Molecular Weight: 241.67
• Mol File: 68281-43-6.mol

Chemical Properties

• Melting Point: 84-85°
• Boiling Point: 353.4°C at 760 mmHg
• Flash Point: 167.5°C
• Appearance: /
• Density: 1.275g/cm³
• Vapor Pressure: 3.59E-05mmHg at 25°C
• Refractive Index: 1.538
• PKA: 2.48±0.40(Predicted)
• CAS DataBase Reference: 6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE-2-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE-2-CARBOXYLIC ACID ETHYL ESTER(68281-43-6)
• EPA Substance Registry System: 6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE-2-CARBOXYLIC ACID ETHYL ESTER(68281-43-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 68281-43-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE-2-CARBOXYLIC ACID ETHYL ESTER is used as a chemical intermediate for the synthesis of various drugs, contributing to the development of new medicinal compounds.
Used in Medicinal Chemistry Research:
6-CHLORO-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE-2-CARBOXYLIC ACID ETHYL ESTER is being studied for its potential biological activity, with the aim of discovering its possible use as a medicinal agent, which could lead to advancements in therapeutic treatments.

InChI:InChI=1/C11H12ClNO3/c1-2-15-11(14)10-6-13-8-5-7(12)3-4-9(8)16-10/h3-5,10,13H,2,6H2,1H3

Upstream product

• 3674-13-3 2,3-dibromopropionic acid ethyl ester 
• 95-85-2 2-hydroxy-5-chloro-aniline 

Downstream Products

• 176383-57-6 (6-chloro-3,4-dihydro-2H-1,4-benzoxazine-2-yl)methanol 
• 391873-67-9 ethyl 4-acetyl-6-chloro-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylate 

Relevant articles and documents

SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.

Benzo six-membered nitrogen heterocyclic compound, preparation method and applications

The present invention provides a benzo six-membered nitrogen heterocyclic compound, a preparation method and applications, wherein the benzo six-membered nitrogen heterocyclic compound has a structurerepresented by a formula I or formula II, and can effectively inhibit the bromine domain receptor and effectively inhibit the proliferation of cancer cells. Compared with the existing reported structure types, the compound of the present invention has different binding mode, has high inhibitory activity, can be used as a drug for treating cancer, cell proliferation disorders, inflammatory diseases, autoimmune diseases, septicemia and viral infections, and has good application prospects and high application value.

MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds of formula (I), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. (Formula I).

MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group

Osteoarthritis is a disabling disease characterized by the articular cartilage breakdown. Aggrecanases are potential therapeutic targets for the treatment of this pathology. At the starting point of this project, an acylthiosemicarbazide was discovered to inhibit aggrecanase-2. The acylthiosemicarbazide Zn binding group is also a convenient linker for library synthesis. A focused library of 920 analogs was thus prepared and screened to establish structure-activity relationships. The modification of the acylthiosemicarbazide was also explored. This strategy combining library design and discrete compounds synthesis yielded inhibitor 35, that is highly selective for aggrecanases over a panel of metalloproteases and inhibits the degradation of native fully glycosylated aggrecan. A docking study generated binding conformations explaining the structure-activity relationships.

New non-hydroxamic ADAMTS-5 inhibitors based on the 1,2,4-triazole-3-thiol scaffold

In this Letter we describe the design, synthesis, screening, and optimization of a new family of ADAMTS-5 inhibitors. These inhibitors display an original 1,2,4-triazole-3-thiol scaffold as a putative zinc binding-group. In vitro results are rationalized

Synthesis and biological evaluation of new 2-(4,5-dihydro-1H-imidazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine derivatives

2-(4,5-Dihydro-1H-imidazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine derivatives and tricyclic analogues with a fused additional ring on the nitrogen atom of the benzoxazine moiety have been prepared and evaluated for their cardiovascular effects as potential antihypertensive agents. The imidazoline ring was generated by reaction of the corresponding ethyl ester with ethylenediamine. Affinities for imidazoline binding sites (IBS) I1 and I2 and α1 and α2 adrenergic receptors were evaluated as well as the effects on mean arterial blood pressure (MAP) and heart rate (HR) of spontaneously hypertensive rats. With few exceptions the most active compounds on MAP were those with high affinities for IBS and α2 receptor. Among these, compound 4h was the most interesting and is now, together with its enantiomers, under complementary pharmacological evaluation.

A straightforward route to 4H-1,4-benzoxazine-2-carbaldehydes by Swern oxidation

Swern oxidation of saturated (1,4-benzoxazine-2-yl)-methanols 2 furnished 4H-1,4-benzoxazine-2-carbaldehydes 3, which possess an α,β ethylenic bond. The reactivity of these compounds was examined.

Lipogenesis control by esters of benzoxazinecarboxylic acids

Lipogenesis in mammals is inhibited by esters of 3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acids.